Cargando…

SOBA (soluble oligomer binding assay): A breakthrough or the early diagnosis of Alzheimer's disease

Detalles Bibliográficos
Autores principales:	Sheikh, Ayesha, Mughal, Sanila, Owais, Rabia, Siddiqui, Mishal Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435830/ https://www.ncbi.nlm.nih.gov/pubmed/37599661 http://dx.doi.org/10.1002/hsr2.1492

Ejemplares similares

SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers
por: Shea, Dylan, et al.
Publicado: (2022)

Reply: Soluble oligomers or insoluble fibrils?
por: Mate de Gerando, Anastasie, et al.
Publicado: (2023)

Artificial tears: Promising treatment or silent threat to public health?
por: Mughal, Sanila, et al.
Publicado: (2023)

FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology
por: Sheikh, Ayesha, et al.
Publicado: (2022)

The emergence of mpox in Pakistan: An urgent call for preparedness and response
por: Mughal, Sanila, et al.
Publicado: (2023)

SOBA: sequence ontology bioinformatics analysis
por: Moore, Barry, et al.
Publicado: (2010)

Novel breakthrough in the treatment of sphingomyelinase deficiency
por: Sultan, Wania, et al.
Publicado: (2023)

Emergency in obese patients: a reply to SOBA UK
por: Di Giacinto, Ida, et al.
Publicado: (2022)

Prophylactic ceftizoxime for elective cesarean delivery at Soba Hospital, Sudan
por: Osman, Bashier, et al.
Publicado: (2013)

Health hazards related to Soba sewage treatment plant, Sudan
por: Abdelmoneim, Rasha Osman Abdelwahab, et al.
Publicado: (2017)

SOBA UK response to “emergencies in obese patients: a narrative review”
por: McKechnie, Andrew, et al.
Publicado: (2021)

Celebrating breakthrough in dental diagnostics: FDA approval of an AI model for diagnosis of periodontal diseases: A correspondence
por: Khan, Ayesha, et al.
Publicado: (2023)

Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease
por: Gutierrez, Berenice A., et al.
Publicado: (2022)

Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
por: Habashi, Maram, et al.
Publicado: (2022)

Assessment of early functional outcome of lumbar discectomy in Soba and Future hospitals, Khartoum, Sudan 2021
por: Mohammed, DrHussameldin Mohammed Alhassan Ali, et al.
Publicado: (2022)

The Prevalence and Severity of Potential Drug–Drug Interactions in Internal Medicine Ward at Soba Teaching Hospital
por: Hamadouk, Riham M, et al.
Publicado: (2023)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015)

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
por: Hector, Audrey, et al.
Publicado: (2021)

Booster vaccines for COVID-19 vaccine breakthrough cases?
por: Nixon, Douglas F, et al.
Publicado: (2022)

Estrogenicity of Styrene Oligomers: Response to Ohno et al.
por: Ohyama, Ken-ichi, et al.
Publicado: (2002)

Comprehensive overview of human monkeypox: epidemiology, clinical features, pathogenesis, diagnosis and prevention
por: Ali, Eman, et al.
Publicado: (2023)

Estrogenicity of styrene oligomers and assessment of estrogen receptor binding assays.
por: Ohno, Katsutoshi, et al.
Publicado: (2002)

Metallic nanoparticle-coated sutures: a breakthrough in the field of surgery
por: Khan, Abdul Moiz, et al.
Publicado: (2023)

Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
por: Brinkley-Rubinstein, Lauren, et al.
Publicado: (2021)

Booster vaccines for COVID-19 vaccine breakthrough cases? – Authors' reply
por: Krause, Philip R, et al.
Publicado: (2022)

Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata
por: Ali, Eman, et al.
Publicado: (2022)

Breakthrough COVID-19 infections – Analyzing our experience
por: Hussain, Aneela, et al.
Publicado: (2023)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Immunodeficiency Should Be Excluded in Patients With Recurrent Viral Meningitis and Breakthrough COVID-19
por: Finsterer, Josef
Publicado: (2022)

Disruption of Amyloid Plaques Integrity Affects the Soluble Oligomers Content from Alzheimer Disease Brains
por: Jimenez, Sebastian, et al.
Publicado: (2014)

Clinical Considerations During Breakthrough Coronavirus Disease 2019 Infections in Vaccinated Individuals With Autoimmunity
por: Rocco, Joseph M, et al.
Publicado: (2021)

Alzheimer’s research—breakthrough or breakdown?
por: Spires-Jones, Tara L
Publicado: (2021)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

Alzheimer’s Disease, Oligomers, and Inflammation
por: Forloni, Gianluigi, et al.
Publicado: (2018)

Breakthrough cases of COVID-19 in vaccinated United States Veterans with spinal cord injuries and disorders
por: Sankary, Kendl M., et al.
Publicado: (2021)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Celebrating a breakthrough: the first-ever FDA-approved treatment for geographic atrophy: a correspondence
por: Khan, Abdul Moiz, et al.
Publicado: (2023)

Antibody response assessment of immediate breakthrough infections after zero-COVID policy adjustment in China
por: Li, Yanhua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ik3j2odjj87avbvfh2ob8kdqug